IM CANNABIS CORP (IMCC) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:IMCC • CA44969Q4060

1.19 USD
-0.02 (-1.65%)
Last: Feb 4, 2026, 04:04 PM
Fundamental Rating

3

Taking everything into account, IMCC scores 3 out of 10 in our fundamental rating. IMCC was compared to 191 industry peers in the Pharmaceuticals industry. IMCC may be in some trouble as it scores bad on both profitability and health. IMCC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • IMCC had negative earnings in the past year.
  • IMCC had a positive operating cash flow in the past year.
  • IMCC had negative earnings in each of the past 5 years.
  • IMCC had a negative operating cash flow in each of the past 5 years.
IMCC Yearly Net Income VS EBIT VS OCF VS FCFIMCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • IMCC has a Return On Assets of -10.43%. This is in the better half of the industry: IMCC outperforms 66.49% of its industry peers.
  • IMCC's Return On Equity of -88.04% is in line compared to the rest of the industry. IMCC outperforms 40.84% of its industry peers.
Industry RankSector Rank
ROA -10.43%
ROE -88.04%
ROIC N/A
ROA(3y)-119.26%
ROA(5y)-87.85%
ROE(3y)-367.14%
ROE(5y)-273.77%
ROIC(3y)N/A
ROIC(5y)N/A
IMCC Yearly ROA, ROE, ROICIMCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

  • The Gross Margin of IMCC (18.58%) is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of IMCC has grown nicely.
  • IMCC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 18.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y497.26%
GM growth 5YN/A
IMCC Yearly Profit, Operating, Gross MarginsIMCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

  • IMCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for IMCC has been increased compared to 1 year ago.
  • Compared to 5 years ago, IMCC has more shares outstanding
  • The debt/assets ratio for IMCC is higher compared to a year ago.
IMCC Yearly Shares OutstandingIMCC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
IMCC Yearly Total Debt VS Total AssetsIMCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • IMCC has an Altman-Z score of -7.31. This is a bad value and indicates that IMCC is not financially healthy and even has some risk of bankruptcy.
  • IMCC has a worse Altman-Z score (-7.31) than 66.49% of its industry peers.
  • The Debt to FCF ratio of IMCC is 4.09, which is a neutral value as it means it would take IMCC, 4.09 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 4.09, IMCC belongs to the top of the industry, outperforming 85.34% of the companies in the same industry.
  • A Debt/Equity ratio of 2.52 is on the high side and indicates that IMCC has dependencies on debt financing.
  • IMCC has a Debt to Equity ratio of 2.52. This is in the lower half of the industry: IMCC underperforms 79.58% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.52
Debt/FCF 4.09
Altman-Z -7.31
ROIC/WACCN/A
WACC12.05%
IMCC Yearly LT Debt VS Equity VS FCFIMCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 0.72 indicates that IMCC may have some problems paying its short term obligations.
  • With a Current ratio value of 0.72, IMCC is not doing good in the industry: 90.05% of the companies in the same industry are doing better.
  • IMCC has a Quick Ratio of 0.72. This is a bad value and indicates that IMCC is not financially healthy enough and could expect problems in meeting its short term obligations.
  • IMCC has a worse Quick ratio (0.59) than 87.43% of its industry peers.
Industry RankSector Rank
Current Ratio 0.72
Quick Ratio 0.59
IMCC Yearly Current Assets VS Current LiabilitesIMCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 11.98% over the past year.
  • The Revenue has grown by 10.71% in the past year. This is quite good.
  • Measured over the past years, IMCC shows a quite strong growth in Revenue. The Revenue has been growing by 16.64% on average per year.
EPS 1Y (TTM)11.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.09%
Revenue 1Y (TTM)10.71%
Revenue growth 3Y16.64%
Revenue growth 5YN/A
Sales Q2Q%-14.29%

3.2 Future

  • IMCC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.54% yearly.
  • IMCC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.24% yearly.
EPS Next Y86.24%
EPS Next 2Y36.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year41.23%
Revenue Next 2Y26.24%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IMCC Yearly Revenue VS EstimatesIMCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
IMCC Yearly EPS VS EstimatesIMCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -50 -100

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IMCC. In the last year negative earnings were reported.
  • Also next year IMCC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMCC Price Earnings VS Forward Price EarningsIMCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

  • IMCC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. IMCC is cheaper than 99.48% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2.21
EV/EBITDA N/A
IMCC Per share dataIMCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as IMCC's earnings are expected to grow with 36.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.54%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • IMCC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

IM CANNABIS CORP

NASDAQ:IMCC (2/4/2026, 4:04:46 PM)

1.19

-0.02 (-1.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13
Earnings (Next)03-30
Inst Owners18.37%
Inst Owner Change-0.53%
Ins Owners41.71%
Ins Owner ChangeN/A
Market Cap6.25M
Revenue(TTM)54.03M
Net Income(TTM)-4.69M
Analysts82.86
Price TargetN/A
Short Float %2.11%
Short Ratio0.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-17.69%
Min Revenue beat(2)-25.65%
Max Revenue beat(2)-9.73%
Revenue beat(4)1
Avg Revenue beat(4)-9.56%
Min Revenue beat(4)-25.65%
Max Revenue beat(4)9.9%
Revenue beat(8)3
Avg Revenue beat(8)-4.84%
Revenue beat(12)3
Avg Revenue beat(12)-9.88%
Revenue beat(16)5
Avg Revenue beat(16)-5.1%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.16
P/FCF 2.21
P/OCF 2.12
P/B 1.6
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.48
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)0.54
FCFY45.25%
OCF(TTM)0.56
OCFY47.06%
SpS7.6
BVpS0.74
TBVpS-0.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10.43%
ROE -88.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 18.58%
FCFM 7.09%
ROA(3y)-119.26%
ROA(5y)-87.85%
ROE(3y)-367.14%
ROE(5y)-273.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y497.26%
GM growth 5YN/A
F-Score7
Asset Turnover1.21
Health
Industry RankSector Rank
Debt/Equity 2.52
Debt/FCF 4.09
Debt/EBITDA N/A
Cap/Depr 7.98%
Cap/Sales 0.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.72
Quick Ratio 0.59
Altman-Z -7.31
F-Score7
WACC12.05%
ROIC/WACCN/A
Cap/Depr(3y)15.95%
Cap/Depr(5y)83.89%
Cap/Sales(3y)1.45%
Cap/Sales(5y)6.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.09%
EPS Next Y86.24%
EPS Next 2Y36.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)10.71%
Revenue growth 3Y16.64%
Revenue growth 5YN/A
Sales Q2Q%-14.29%
Revenue Next Year41.23%
Revenue Next 2Y26.24%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y66.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year130.87%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y136.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y143.37%
OCF growth 3YN/A
OCF growth 5YN/A

IM CANNABIS CORP / IMCC FAQ

What is the fundamental rating for IMCC stock?

ChartMill assigns a fundamental rating of 3 / 10 to IMCC.


Can you provide the valuation status for IM CANNABIS CORP?

ChartMill assigns a valuation rating of 2 / 10 to IM CANNABIS CORP (IMCC). This can be considered as Overvalued.


Can you provide the profitability details for IM CANNABIS CORP?

IM CANNABIS CORP (IMCC) has a profitability rating of 2 / 10.


What is the earnings growth outlook for IM CANNABIS CORP?

The Earnings per Share (EPS) of IM CANNABIS CORP (IMCC) is expected to grow by 86.24% in the next year.